Psoriasis Club
  • Forum
  • Home
  • Portal
  • Member List
  • Psoriasis Score
  • PQOLS
  • What is psoriasis
  • Search
  • Help
Hello Guest, Welcome To The Psoriasis Club Forum. We are a self funded friendly group of people who understand.
Never be alone with psoriasis, come and join us. (Members see a lot more than you)
wave
Login Register
Login
Username:
Password:
Lost Password?
 
Psoriasis Club › HealthHealth Boards › Psoriasis In The News v
« Previous 1 … 3 4 5 6 7 … 54 Next »

Bimzelx gets recommendation for psoriatic arthritis in the EU

Threaded Mode
Bimzelx gets recommendation for psoriatic arthritis in the EU
Fred Offline
I Wanted To Change the World But Got Up Far Too Late.
Moderator
Posts: 66,968
Threads: 3,888
Joined: Aug 2011
Gender: Male
Location: France
Psoriatic Arthritis Score: 1
PQOLS: 1
Treatment: Bimzelx / Coconut Oil
#1
News  Fri-28-04-2023, 13:32 PM
Bimzelx received positive opinion by the Committee for Medicinal Products for Human Use (CHMP) for use in patients with psoriatic arthritis.

Quote:
UCB, a global biopharmaceutical company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued positive opinions recommending granting marketing authorization for bimekizumab in the European Union (EU) for the treatment of adults with active axial spondyloarthritis (axSpA) and for adults with active psoriatic arthritis (PsA). AxSpA is an indication that spans both non-radiographic axSpA (nr-axSpA) and ankylosing spondylitis (AS), also known as radiographic axSpA (r-axSpA). If approved by the European Commission (EC), these would represent the second and third indications for bimekizumab in the EU, following its initial approval for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy in August 2021.
 
“The positive CHMP opinion for two new indications for bimekizumab in Europe is a significant step towards our goal of delivering differentiated treatment options to patients. If approved, bimekizumab would be the first treatment for psoriatic arthritis and axial spondyloarthritis that inhibits IL-17F in addition to IL-17A. Positive results from the four Phase 3 clinical studies in PsA and axSpA showed that treatment with bimekizumab consistently resulted in deep levels of response that were rapid and sustained,” said Emmanuel Caeymaex, Executive Vice President, Immunology Solutions and Head of U.S., UCB. 

In active PsA, the CHMP recommended approval of bimekizumab alone or in combination with methotrexate, for the treatment of adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs. The CHMP opinion is based on data from the Phase 3 BE COMPLETE and BE OPTIMAL studies recently published in The Lancet.  The two studies met their primary and all ranked secondary endpoints with statistical significance at week 16. Long-term data from BE OPTIMAL showed that bimekizumab demonstrated sustained responses to week 52.

The CHMP positive opinions on bimekizumab in active PsA and active axSpA will be referred to the EC, which will deliver a final decision within approximately two months. The marketing authorization will be valid in all member states of the European Union as well as Iceland, Norway, Northern Ireland and Liechtenstein.
Bimekizumab is currently approved in the European Union for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.

Source: ucb.com

Bimzelx (bimekizumab)
Quote
Fred Offline Author
I Wanted To Change the World But Got Up Far Too Late.
Moderator
Posts: 66,968
Threads: 3,888
Joined: Aug 2011
Gender: Male
Location: France
Psoriatic Arthritis Score: 1
PQOLS: 1
Treatment: Bimzelx / Coconut Oil
#2
Fri-09-06-2023, 13:28 PM
Update:

Quote:
UCB today announced that the European Commission (EC) has granted marketing authorisation for BIMZELX® (bimekizumab) for the treatment of adults with active psoriatic arthritis (PsA) and adults with active axial spondyloarthritis (axSpA) including non-radiographic axSpA (nr-axSpA) and ankylosing spondylitis (AS), also known as radiographic axSpA. These approvals in the European Union (EU) represent the first marketing authorizations for bimekizumab in PsA and axSpA worldwide, and the second and third indications for bimekizumab in the EU, following its approval for the treatment of moderate to severe plaque psoriasis in August 2021.

“The European Commission’s parallel approval of bimekizumab in PsA and axSpA builds on the momentum created since its first approval in moderate to severe plaque psoriasis and marks an exciting milestone offering healthcare professionals and patients the first IL-17A and IL-17F inhibitor for treatment of these diseases,” said Emmanuel Caeymaex, Executive Vice President, Immunology Solutions and Head of U.S., UCB. “The extended approval for bimekizumab in the European Union reflects our commitment to address unmet patient needs, improve patient outcomes and raise standards of care.” 

In PsA, bimekizumab is approved alone or in combination with methotrexate for the treatment of adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (DMARDs). In axSpA, bimekizumab is approved for the treatment of adults with active nr-axSpA with objective signs of inflammation as indicated by elevated C-reactive protein and/or magnetic resonance imaging who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs, and for the treatment of adults with active AS who have responded inadequately or are intolerant to conventional therapy.

Source: ucb.com
Quote
Forest Walker Offline
100 + Member I'd Rather Be Roller Skating

100 + Member I Just Cant Stop !
Posts: 9,448
Threads: 128
Joined: Aug 2021
Gender: Female
Location: Northern Washington State
Treatment: Humira, Moisturizers, Triamcinolonoe Acetonide
#3
Sat-10-06-2023, 14:33 PM
(Fri-09-06-2023, 13:28 PM)Fred Wrote: Update:

Quote:
UCB today announced that the European Commission (EC) has granted marketing authorisation for BIMZELX® (bimekizumab) for the treatment of adults with active psoriatic arthritis (PsA) and adults with active axial spondyloarthritis (axSpA) including non-radiographic axSpA (nr-axSpA) and ankylosing spondylitis (AS), also known as radiographic axSpA. These approvals in the European Union (EU) represent the first marketing authorizations for bimekizumab in PsA and axSpA worldwide, and the second and third indications for bimekizumab in the EU, following its approval for the treatment of moderate to severe plaque psoriasis in August 2021.

“The European Commission’s parallel approval of bimekizumab in PsA and axSpA builds on the momentum created since its first approval in moderate to severe plaque psoriasis and marks an exciting milestone offering healthcare professionals and patients the first IL-17A and IL-17F inhibitor for treatment of these diseases,” said Emmanuel Caeymaex, Executive Vice President, Immunology Solutions and Head of U.S., UCB. “The extended approval for bimekizumab in the European Union reflects our commitment to address unmet patient needs, improve patient outcomes and raise standards of care.” 

In PsA, bimekizumab is approved alone or in combination with methotrexate for the treatment of adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (DMARDs). In axSpA, bimekizumab is approved for the treatment of adults with active nr-axSpA with objective signs of inflammation as indicated by elevated C-reactive protein and/or magnetic resonance imaging who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs, and for the treatment of adults with active AS who have responded inadequately or are intolerant to conventional therapy.

Source: ucb.com


This is good news!   Clap
Quote
« Next Oldest | Next Newest »


Possibly Related Threads…
Thread Author Replies Views Last Post
News Could c-reactive protein predict psoriatic arthritis Fred 7 1,162 Mon-07-04-2025, 13:15 PM
Last Post: Forest Walker
News Treatment goals with psoriatic arthritis Fred 5 1,055 Thu-27-03-2025, 04:29 AM
Last Post: mataribot
News Cosentyx and erosion progression in psoriatic arthritis Fred 0 409 Fri-14-03-2025, 12:03 PM
Last Post: Fred
News Circadian rhythms and psoriatic arthritis Fred 1 480 Mon-10-03-2025, 20:28 PM
Last Post: Caroline
News Bimzelx five year data Fred 2 696 Sat-08-03-2025, 16:34 PM
Last Post: Fred



Users browsing this thread: 1 Guest(s)
    About | Contact us | Login | Register | Home | Cookies/GDPR | RSS Syndication | Portal | Types Of Psoriasis | Psoriasis Score | Members Only Boards
    Copyright © 2010 - 2025 Psoriasis Club | All Rights Reserved | Founded May 2010 | Psoriasis Club Is Self Funded Without Sponsors Or Donations | Software by MyBB | Social
Linear Mode
Threaded Mode